Jeil Pharm (002620 KO) stock market data APIs
₩8665.4997
21.3(0.2%)
as of September 15, 2025
Try our APIs with
free plan!
Jeil Pharm Financial Data Overview
Price chart is built with
Anychart
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms in the areas of anti-bacteria and anti-fungal, anti-virus, cardiovascular, endocrinology, neurology, gastrointestinal, urology, oncology, anti-histamine, rheumatology, respiratory, otolaryngological, heaptic, laxatives, and purgatives. The company exports its products to approximately 40 countries in the Association of Southeast Asian Nations, Central and South America, Africa, etc. The company was founded in 1959 and is headquartered in Seoul, South Korea.
Prev. Close
8665.4997
Open
8686.8015
High
8845.4031
Low
8592.5994
52 wk Range
6950-11000.6391
Market Cap
132 634 M
Shares Outstanding
15 351 K
Revenue
735 787 M
EPS
95.1038
Dividends (Yield)
0.0057
Beta
0.717
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Jeil Pharm data using free add-ons & libraries
Get Jeil Pharm Fundamental Data
Jeil Pharm Fundamental data includes:
- Net Revenue: 735 787 M
- EBITDA: 29 482 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Jeil Pharm News
New
Daré Bioscience to Host First Quarter 2022 Financial Results and Company Update Conference Call and Webcast on May 12, 2022
Daré Bioscience, Inc. SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call ...
Daré Bioscience to Participate in Upcoming Conference
Daré Bioscience, Inc. SAN DIEGO, April 14, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the...
Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-HRT1
Daré Bioscience, Inc. Prior Phase 1 Study Results Support Potential as the First Monthly Therapy for both the Vasomotor and the Vaginal Symptoms of Menopause Current Phase 1/2 Study will Collect Sy...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
